Back to results
US 12,466,879 B2Granted
Complement factor D antagonist antibodies and conjugates thereof
AssigneeKodiak Sciences Inc.
InventorsDaniel Victor Perlroth, Wah Yuen To, Hong Liang, Rachel Marie DeVay Jacobson, Fernando Corrêa
Life of this patent
Estimating the term…
Abstract
The present invention provides antagonizing antibodies that bind to complement factor D (CFD), conjugates thereof, and methods of using same. The anti-CFD antibodies can be used therapeutically alone or in combination with other therapeutics to treat age related macular degeneration and other diseases.
Claims22
A conjugate comprising:
- an isolated antagonistic antibody that binds to complement factor D (CFD), the antibody comprising:
- a CDRH1 that is the CDRH1 in SEQ ID NO:
- 520;
- a CDRH2 that is the CDRH2 in SEQ ID NO:
- 520;
- a CDRH3 that is the CDRH3 in SEQ ID NO:
- 520;
- a CDRL1 that is the CDRL1 in SEQ ID NO:
- 525;
- a CDRL2 that is the CDRL2 in SEQ ID NO:
- 525;
- a CDRL3 that is the CDRL3 in SEQ ID NO:
- 525;
- at least one of the following mutations (EU numbering):
- L234A, L235A, and G237A;
- and
- at least one of the following mutations (EU numbering):
- Q347C or L443C;
- and
- a polymer, wherein the polymer is covalently attached to the antibody.
17 more elements
A conjugate comprising:
- (a) an isolated antagonist antibody that specifically binds to complement factor D (CFD), wherein the antibody comprises:
- a heavy chain variable region (VH) comprising:
- a VH complementarity determining region 1 (CDRH1) that is the CDRH1 in SEQ ID NO:
- 520;
- a CDRH2 that is the CDRH2 in SEQ ID NO:
- 520;
- a CDRH3 that is the CDRH3 in SEQ ID NO:
- 520;
- and
- a light chain variable region (VL) comprising:
- a VL complementarity determining region 1 (CDRL1) comprising H31, N33, G34 or E34 or F34 or S34, D35 or E35, T36 or S36 or V36, Y37, L38 or I38, and E39 (EU numbering);
- a CDRL2 comprising L51 or H51, 153 or V53, and K55 (EU numbering);
- and
- a CDRL3 comprising F94 or L94, Q95, G96, S97, V99 or N99 or Q99 or W99, P100, and P101 or V101 (EU numbering);
- and
- (b) a phosphorylcholine containing polymer, wherein the polymer is covalently bonded to the antibody.
13 more elements
A conjugate comprising:
- an isolated antagonist antibody that specifically binds to complement factor D (CFD), the antibody comprising:
- a heavy chain variable region (VH) comprising 3 CDRs of the CDRs in SEQ ID NO:
- 339;
- and a light chain variable region (VH) comprising 3 CDRs of the CDRs in SEQ ID NO:
- 340;
- or
- a VH comprising 3 CDRs of the CDRs in SEQ ID NO:
- 343;
- and a VL comprising 3 CDRs of the CDRs in SEQ ID NO:
- 344;
- or
- a VH comprising 3 CDRs of the CDRs in SEQ ID NO:
- 435;
- and a VL comprising 3 CDRs of the CDRs in SEQ ID NO:
- 436;
- or
- a VH comprising 3 CDRs of the CDRs in SEQ ID NO:
- 437;
- and a VL comprising 3 CDRs of the CDRs in SEQ ID NO:
- 438;
- or
- a VH comprising 3 CDRs of the CDRs in SEQ ID NO:
- 441;
- and a VL comprising 3 CDRs of the CDRs in SEQ ID NO:
- 442;
- or
- a VH comprising 3 CDRs of the CDRs in SEQ ID NO:
- 443;
- and a VL comprising 3 CDRs of the CDRs in SEQ ID NO:
- 444;
- or
- a VH comprising 3 CDRs of the CDRs in SEQ ID NO:
- 445;
- and a VL comprising 3 CDRs of the CDRs in SEQ ID NO:
- 446;
- or
- a VH comprising 3 CDRs of the CDRs in SEQ ID NO:
- 447;
- and a VL comprising 3 CDRs of the CDRs in SEQ ID NO:
- 448;
- or
- a VH comprising 3 CDRs of the CDRs in SEQ ID NO:
- 351;
- and a VL comprising 3 CDRs of the CDRs in SEQ ID NO:
- 352;
- or
- a VH comprising 3 CDRs of the CDRs in SEQ ID NO:
- 373;
- and a VL comprising 3 CDRs of the CDRs in SEQ ID NO:
- 374;
- or
- a VH comprising 3 CDRs of the CDRs in SEQ ID NO:
- 387;
- and a VL comprising 3 CDRs of the CDRs in SEQ ID NO:
- 388;
- or
- a VH comprising 3 CDRs of the CDRs in SEQ ID NO:
- 385;
- and a VL comprising 3 CDRs of the CDRs in SEQ ID NO:
- 386;
- or
- a VH comprising 3 CDRs of the CDRs in SEQ ID NO:
- 389;
- and a VL comprising 3 CDRs of the CDRs in SEQ ID NO:
- 390;
- or
- a VH comprising 3 CDRs of the CDRs in SEQ ID NO:
- 391;
- and a VL comprising 3 CDRs of the CDRs in SEQ ID NO:
- 392;
- or
- a VH comprising 3 CDRs of the CDRs in SEQ ID NO:
- 509;
- and a VL comprising 3 CDRs of the CDRs in SEQ ID NO:
- 510;
- or
- a VH comprising 3 CDRs of the CDRs in SEQ ID NO:
- 485;
- and a VL comprising 3 CDRs of the CDRs in SEQ ID NO:
- 486;
- or
- a VH comprising 3 CDRs of the CDRs in SEQ ID NO:
- 495;
- and a VL comprising 3 CDRs of the CDRs in SEQ ID NO:
- 496;
- or
- a VH comprising 3 CDRs of the CDRs in SEQ ID NO:
- 471;
- and a VL comprising 3 CDRs of the CDRs in SEQ ID NO:
- 472;
- or
- a VH comprising 3 CDRs of the CDRs in SEQ ID NO:
- 337;
- and a VL comprising 3 CDRs of the CDRs in SEQ ID NO:
- 338;
- or
- a VH comprising 3 CDRs of the CDRs in SEQ ID NO:
- 423;
- and a VL comprising 3 CDRs of the CDRs in SEQ ID NO:
- 424;
- or
- a VH comprising 3 CDRs of the CDRs in SEQ ID NO:
- 439;
- and a VL comprising 3 CDRs of the CDRs in SEQ ID NO:
- 440;
- or
- a VH comprising 3 CDRs of the CDRs in SEQ ID NO:
- 459;
- and a VL comprising 3 CDRs of the CDRs in SEQ ID NO:
- 460;
- or
- a VH comprising 3 CDRs of the CDRs in SEQ ID NO:
- 477;
- and a VL comprising 3 CDRs of the CDRs in SEQ ID NO:
- 478;
- or
- a VH comprising 3 CDRs of the CDRs in SEQ ID NO:
- 461;
- and a VL comprising 3 CDRs of the CDRs in SEQ ID NO:
- 462;
- or
- a VH comprising 3 CDRs of the CDRs in SEQ ID NO:
- 493;
- and a VL comprising 3 CDRs of the CDRs in SEQ ID NO:
- 494;
- and
- a phosphorylcholine containing polymer, wherein the polymer is covalently bonded to the antibody.
124 more elements
Dependencies are inferred from the claim text.